Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Genmab A/S Sponsored ADR has a “Moderate Buy” consensus rating from 12 analysts, with eight Buy ratings, one Strong Buy, two Holds, and one Sell. The average 12-month price target is about $38.21.
• Several firms recently turned more bullish on the stock, including Truist Financial and HC Wainwright, while Goldman Sachs and BNP Paribas Exane both upgraded their ratings. Recent price targets from analysts generally cluster around the $40 level.
• The shares were trading at $28.72 in the article, below the average analyst target, and the company has a market cap of $17.91 billion. Institutional investors also remain involved, with hedge funds and other institutions owning 7.07% of the stock.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $38.2143.

A number of research firms have issued reports on GMAB. Truist Financial initiated coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a "buy" rating and a $40.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Genmab A/S from a "neutral" rating to a "buy" rating in a report on Wednesday, April 22nd. BNP Paribas Exane raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, April 22nd. HC Wainwright boosted their price target on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, July 2nd. Finally, Wolfe Research started coverage on shares of Genmab A/S in a research report on Friday, March 27th. They issued an "outperform" rating and a $32.00 price objective for the company.

Genmab A/S Stock Down 0.9%

Shares of NASDAQ:GMAB opened at $28.72 on Friday. The business's 50 day moving average is $26.62 and its 200 day moving average is $28.42. Genmab A/S has a 12-month low of $21.00 and a 12-month high of $35.43. The stock has a market cap of $17.91 billion, a price-to-earnings ratio of 21.76, a PEG ratio of 1.84 and a beta of 0.84. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently modified their holdings of GMAB. Orbis Allan Gray Ltd increased its position in shares of Genmab A/S by 30.2% during the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company's stock valued at $444,089,000 after acquiring an additional 3,340,456 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its position in Genmab A/S by 84.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,039,834 shares of the company's stock worth $216,827,000 after purchasing an additional 3,222,983 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Genmab A/S by 36.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company's stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the period. Renaissance Technologies LLC grew its stake in Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock valued at $118,442,000 after purchasing an additional 921,700 shares during the period. Finally, First Trust Advisors LP increased its position in shares of Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company's stock valued at $66,038,000 after purchasing an additional 1,126,069 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company's work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab's portfolio includes products developed in collaboration with leading global pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.